Boston Scientific Total Cost of Revenue decreased by 1.1% to $1.59B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.4%, from $1.45B to $1.59B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 13.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $945.00M | $900.00M | $972.00M | $955.00M | $1.01B | $979.00M | $1.01B | $1.04B | $1.06B | $1.10B | $1.15B | $1.21B | $1.27B | $1.31B | $1.47B | $1.45B | $1.64B | $1.52B | $1.61B | $1.59B |
| QoQ Change | — | -4.8% | +8.0% | -1.7% | +5.9% | -3.2% | +3.3% | +2.9% | +1.7% | +4.1% | +4.2% | +5.4% | +5.0% | +3.3% | +11.7% | -0.9% | +12.7% | -7.0% | +5.6% | -1.1% |
| YoY Change | — | — | — | — | +7.0% | +8.8% | +4.0% | +8.9% | +4.6% | +12.5% | +13.5% | +16.3% | +20.0% | +19.2% | +27.8% | +20.2% | +28.9% | +16.1% | +9.7% | +9.4% |